Judge’s ruling on HHS’ vaccine overhaul spurs questions about RSV shot availability

A federal judge’s March 16 ruling blocking much of HHS’ recent vaccine policy overhaul is raising new questions about access to respiratory syncytial virus preventive shots for infants. 

In the decision, the U.S. District Court for the District of Massachusetts invalidated actions taken by members appointed to the CDC’s Advisory Committee on Immunization Practices after HHS Secretary Robert F. Kennedy Jr. restructured the panel in June. The court found the committee was improperly constituted and vacated its recommendations, effectively reinstating the prior childhood immunization schedule and limiting the authority of the reconfigured advisory group.

In January, the CDC adopted a revised vaccine schedule that cut the number of vaccines routinely recommended for children and adolescents from 18 to 11.

The March 16 ruling has created near-term uncertainty for clinicians, states and public health officials, who are working to understand its implications for vaccine policy and coverage, The New York Times reported. Experts told the news outlet that the back-and-forth on vaccine policy is fueling confusion across care settings, particularly as the Trump administration is expected to appeal the decision, raising the possibility that the policy landscape could change again within days.

One area of concern is access to monoclonal antibody products that protect against RSV. Because at least one product was added to federal recommendations under the now-invalidated advisory committee, its coverage status is unclear. The disruption could affect whether certain RSV preventive therapies remain available at no cost to eligible children, depending on how federal agencies and payers respond in the coming weeks.

“It would be unfortunate if the court ruling were to limit access to a critical prevention tool for infants and young children, especially as R.S.V. activity is rising, with the highest rates of severe illness among those under age 4,” Robert Hopkins Jr., MD, medical director for the National Foundation for Infectious Diseases, told the Times. 

The post Judge’s ruling on HHS’ vaccine overhaul spurs questions about RSV shot availability appeared first on Becker’s Hospital Review | Healthcare News & Analysis.